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Abstract
Introduction: The hypothesis that paracetamol might increase the risk of asthma and other allergic diseases have gained
support from a range of independent studies. However, in studies based in developed countries, the possibility that
paracetamol and asthma are associated through aspirin avoidance is difficult to exclude.
Objectives: To explore this hypothesis among women in a developing country, where we have previously reported aspirin
avoidance to be rare.
Methods: In 2005/6 a population based cohort of 1065 pregnant women was established in Butajira, Ethiopia and baseline
demographic data collected. At 3 years post birth, an interview-based questionnaire administered to 945 (94%) of these
women collected data on asthma, eczema, and hay fever in the past 12 month, frequency of paracetamol use and potential
confounders. Allergen skin tests to Dermatophagoides pteronyssinus and cockroach were also performed. The independent
effects of paracetamol use on allergic outcomes were determined using multiple logistic regression analysis.
Findings: The prevalence of asthma, eczema and hay fever was 1.7%, 0.9% and 3.8% respectively; of any one of these
conditions 5.5%, and of allergen sensitization 7.8%. Paracetamol use in the past month was reported by 29%, and
associations of borderline significance were seen for eczema (adjusted OR (95% CI) = 8.51 (1.68 to 43.19) for 1–3 tablets and
2.19 (0.36 to 13.38) for $4 tablets, compared to no tablets in the past month; overall p = 0.055) and for ‘any allergic
condition’ (adjusted OR (95% CI) = 2.73 (1.22 to 6.11) for 1–3 tablets and 1.35 (0.67 to 2.70) for $4 tablets compared to 0 in
the past month; overall p = 0.071).
Conclusions: This study provides further cross-sectional evidence that paracetamol use increases the risk of allergic disease.
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Introduction
There is now increasing and convincing epidemiological evidence
from a range of independent studies implicating paracetamol use in
the etiology of asthma and other allergic disease[1–3]. Previously our
group has reported a dose-response relationship between paraceta-
mol intake and self-reported wheeze, rhinitis and eczema in an
Ethiopian population in which confounding by indication (implying
that the drug might be given for symptoms of the disease or other
conditions) was unlikely to play a role [4;5]. Themulticountry ISAAC
phase three study reported an association of paracetamol use in the
first year of life with current wheeze, symptoms of rhinoconjunctivitis
and eczema in a very large sample of children from 31 countries[6].
Paracetamol use was similarly associated with the risk of severe
asthma symptoms with population-attributable risk estimates ranging
from 22% to 38% [6]. The adverse effect of paracetamol on asthma
has also been reported with exposure in utero[7] and during
infancy,[5;8] in childhood[6;9] and adults [1;3;4;10–14].
The observation that higher paracetamol use may explain the
increasing prevalence of asthma in English-speaking countries[13–
15] and other regions of the world[6;9] is intriguing and suggests
paracetamol as a putative risk factor for the development of
asthma[2]. Whilst evidence is lacking on effects of therapeutic
doses of paracetamol, it is biologically plausible that paracetamol
may be involved in the etiology of asthma through glutathione
depletion in the lung and reduced antioxidant capacity[16;17].
This depletion may also cause a shift from Th1 to Th2 cytokine
production favoring allergic disorders[17]. Alternatively, paracet-
amol might influence COX-2 activity and production of
prostaglandins E2[15], which in turn favours a T-helper type-2
(Th2) immune dominance. Limited evidence also exists for pro-
inflammatory effects of therapeutic doses of paracetamol through
stimulation of the transient receptor potential ankyrin-1 channel
[18].
In studies based in developed countries, the possibility that
paracetamol and asthma are associated through reverse causation
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and avoidance of aspirin in people with asthma is difficult to
exclude. We have therefore explored this hypothesis in a
population of Ethiopian women among whom we have previously
established that awareness of the potential dangers of aspirin use in
asthma is very low and systematic avoidance of aspirin by
individuals with allergic symptoms is remarkably rare[4].
Methods
Study area
The Butajira Rural Health Program (BRHP), cantered on the
Butajira Demographic Surveillance Site (DSS), is located in
southern Ethiopia, 130 km away from the capital Addis Ababa. It
contains a dynamic cohort with an established data collection
system covering more than 40,000 people living in 10 adminis-
trative areas (one urban and nine rural), details of which have been
described elsewhere.[19] The DSS population contains 13,268
women of reproductive age[19]. A previous study in the source
population reported the prevalence of paracetamol use to be 42%
and showed no difference in use between urban and rural
residents, between males and females or across educational
levels[4]. More than three-quarters of the population knew
paracetamol was different from aspirin[20].
Study design and the birth cohort women
The birth cohort we report on is nested in the BRHP, and was
established between July 2005 and February 2006. Full details
have been described elsewhere[5;21;22]. In brief, pregnant women
aged 15 to 49 years and in their third trimester were identified by
the BRHP enumerators in the course of quarterly surveillance
interviews and 1065 (86% of eligible) women were recruited in the
birth cohort. Non-participating women did not differ from
participating women in respect to socio-demographic character-
istics, details of which were reported elsewhere[22]. Participating
women gave birth to 1006 singleton live babies and have been
followed in the cohort. The study reported here is a population
based study of these birth cohort women three years post birth to
investigate the association between paracetamol use and allergic
diseases and sensitization (Fig 1).
Data collection and measures
The Amharic translation of the International Union Against
Tuberculosis and Lung Disease (IUALTD) bronchial symptoms
questionnaire was administered to each woman. These measure-
ments have been used previously in the same setting[4] and
validated against free-running exercise test or bronchodilator
response to inhaled salbutamol[23]; and were administered by
data collectors known to the women since the establishment of the
birth cohort. Women’s history allergic was measured by using
three questions: asthma (‘In the last 12 months have you had asthma?’),
hay fever (‘In the last 12 months have you had problems with sneezing or
running nose when not have cold or flu, or problems with itchy watery eyes?’)
and eczema (‘In the last 12 months have you had an itchy skin condition
affecting the skin creases (front of the elbow, behind the knees, the front of the
ankles, around the neck, or around the eyes?’). We measured allergen skin
sensitization to Dermatophagoides pteronyssinus and cockroach allergen
(Blattella germanica) (Biodiagnostics, Upton-upon-Severn, UK) using
skin-prick lancets on the palmar surface of the forearm of each
woman. Glycerol saline and histamine dihydrochloride were used
as negative and positive controls, respectively. To determine
frequency of paracetamol use, women were asked "Have you
taken any paracetamol in the last year?" and, if they responded
yes, further asked "How many tablets of paracetamol have you
taken in the last month?"
Questions on potential confounders including area of residence
(urban/rural), age of the women, education and occupation of the
women, type of roof and wall, cooking site, domestic fuel use,
presence of animals in the compound, insecticide use, second hand
smoke (the prevalence of women’s smoking is very rare in this
population), and sanitation were also included.
Data analysis
Questionnaire and skin test data were double-entered into
EpiData version 3.1 (EpiData Denmark). The datasets were
cleaned, coded, and merged ready for analysis using Stata 11
(Statacorp, College Station Texas, USA). The primary outcome
variables were asthma, hay fever, eczema and allergic sensitization
to D. pteronyssinus and/or cockroach allergen. A positive test was
defined as an average of two perpendicular wheal diameters, one
of which was the maximum measurable diameter, of at least 3 mm
greater than the saline control response. Sensitization to either D.
pteronyssinus or cockroach allergen was defined as ‘any sensitization’
and a positive response to one or more of asthma, hay fever and
eczema was defined as ‘any allergic condition.’ Paracetamol use in
the past month was categorized as ‘none’, ‘1–3 tablets’ and ‘$4
tablets’ similar to our previous paracetamol dose categories
reported elsewhere[4]. The univariate association between para-
cetamol use and each outcome variable was assessed by computing
odds ratios (ORs) and associated 95% confidence intervals (CIs)
using binary logistic regression analysis. The independent effects of
paracetamol use on the allergic outcomes were determined using
multiple logistic regression analysis controlling for age of the
women, urban and rural area of residence and women education.
We have further explored the impact of controlling for other
potential confounders listed in Table 1.
Study power
For an outcome with approximately 6% prevalence, our sample
of 945 women provided 80% power at 95% significance level to
detect an odds ratio of 2.2, for use of paracetamol $1 tablets/
month compared with none.
Ethics statement
The study was approved by the ethics committee of Nottingham
University, United Kingdom and the ethics committee of the
Ethiopian Science and Technology Ministry. Written, informed
consent was obtained from all participants in keeping with
requirements of the Ethiopia ethics committee.
Results
Demographics of the cohort women
Nine hundred forty five (94%) women in the cohort were
followed up and responded to the core allergy and environmental
questionnaire, and 943 (99.8%) provided skin test data. The
majority of them were rural dwellers (88%) and nearly half aged
between 25–34 years (Table 1). Only 20% of the women had any
formal education and over 80% were housewives (Table 1). Most
lived in houses with thatched roof (78%), and kept animals inside
overnight (64%; Table 1).
Prevalence of paracetamol use in women
Paracetamol had been used in the last year by 470 (49.7%) women
and in the last month by 272 (28.8%) women. In the last month, 8.7%
of women reported taking 1–3 tablets and 20.1% of women 4 or more
tablets. Use in the past month was unrelated to age and education of
the women, area of residence, roof type, site of cooking, domestic fuel
use or presence of animals inside the house (Table 1).
Paracetamol and Allergic Diseases in Ethiopia
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Prevalence of allergic diseases in women
Asthma was reported in 1.7% (16/945) of women, hay fever in
3.8% (36/945), and eczema in 0.9% (8/945), with a combined
prevalence of ‘any allergic condition’ of 5.5% (52/945) (Table 2).
The prevalence of D. pteronyssinus and cockroach sensitization was
5.6% (53/943) and 2.8% (26/943) respectively, and sensitization
Figure 1. The birth cohort of women.
doi:10.1371/journal.pone.0022551.g001
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to either allergen was found in 7.8% (74/943) of the women
(Table 2). Self-reported asthma, hay fever and eczema were all
more prevalent in urban than rural women, significantly so for
asthma and hay fever (Table 2). There was no significant
difference in allergic sensitization by area of residence (Table 2).
Effects of paracetamol on allergic diseases in women
Table 3 shows that both before and after control for
confounders, paracetamol use was associated with a non-
significant increased risk of asthma, and hay fever, and a
borderline statistically significance increased risk of eczema (ORs
[95% CIs] adjusted for age, area of residence and education
level = 8.51 [1.68 to 43.19] for 1–3 tablets and 2.19 [0.36, 13.38]
for $4 tablets compared with non-use; overall p = 0.055). The
association between paracetamol and ‘any allergic condition’ was
also of borderline statistical significance (p = 0.07) with the greatest
risk in the women taking 1–3 tablets in the past month (adjusted
OR [95% CIs] = 2.73 [1.22 to 6.11] compared to none; Table 3).
No significant association between paracetamol use and allergic
sensitization was seen (Table 3). Further control for other potential
confounders did not materially alter the magnitude of the odds
ratios presented.
Discussion
In this cohort of developing country women, we have
demonstrated borderline significant positive associations between
paracetamol use and reported eczema and ‘any allergic condition’,
independent of age, social class and numerous other potential
confounders. Whilst we found no significant associations between
women’s use of paracetamol and sensitization, the observed effects
were in the expected direction.
We have made use of a cohort of women in a resource-poor
setting to measure allergic outcomes and paracetamol exposure in
a population which can distinguish paracetamol from other
analgesics. Although we have not collected information on aspirin
use, our previous nested study showed that aspirin avoidance
amongst those with allergic diseases is rare[4]. Furthermore, we
have previously shown that use of paracetamol for treating the
symptoms of asthma and other allergic conditions is also rare
[4;20] making reverse causation an unlikely alternative explana-
tion for our current findings. Confounding by use of non-steroidal
anti-inflammatory drugs (NSAIDs) such as ibuprofen is also a
potential issue [24], and previous studies have accounted for these
confounders, as well as aspirin use, in their analy-
ses[7;10;12;14;24]. However, this is an unlikely source of bias in
our study since NSAIDs were not readily available or affordable in
this rural community. We acknowledge that residual confounding
by a factor not measured is difficult to exclude. A further strength
of this study is the inclusion of a large number of potential
confounders like social advantage that might have been linked
with prescription or over-the-counter use of paracetamol.
Table 1. Use of paracetamol in the past month by
demographic and life style factors (N= 945).
Variables N (%)
Paracetamol use in
the past month
n (%) P-value
Area of residence
Urban 117 (12.4) 41 (35.0) 0.110
Rural 828 (87.6) 231 (27.9)
Age of the women
15–24 357 (37.8) 98 (27.5) 0.476
25–34 445 (47.1) 127 (28.5)
35–44 143 (15.1) 47 (32.9)
Education of the women 0.451
No formal education 758 (80.2) 214 (28.2)
Formal education 187 (19.8) 58 (31.0)
Occupation of the women 0.363
Housewife 791 (83.7) 223 (28.2)
Any other job* 154 (16.3) 49 (31.8)
Type of roof 0.246
Thatched 678 (77.5) 188 (27.7)
Corrugated sheet 197 (22.5) 63 (32.0)
Cooking site 0.092
Inside 706 (74.7) 193 (27.3)
Outside 239 (25.3) 79 (33.1)
Indoor kerosene use 0.574
Yes 55 (5.8) 14 (25.5)
No 890 (94.2) 258 (29.0)
Presence of animal 0.818
Yes 602 (63.8) 175 (29.1)
No 342 (36.2) 97 (28.4)
*Farm, trade and profession related and daily labourer.
doi:10.1371/journal.pone.0022551.t001
Table 2. Prevalence of allergic conditions and sensitization among women by area of residence.
Outcome
Overall
n (%)
Urban
n (%)
Rural
n (%)
Crude OR
(95% CI) p-value
Asthma (N= 945) 16 (1.7) 9 (7.7) 7 (0.9) 9.77 (3.57,26.78) ,0.001
Hay fever (N = 945) 36 (3.8) 13 (11.1) 23 (2.8) 4.38 (2.15,8.90) ,0.001
Eczema (N= 945) 8 (0.9) 2 (1.7) 6 (0.7) 2.38 (0.48,11.95) 0.291
Any allergic conditions*(N = 945) 52 (5.5) 19 (16.2) 33 (4.0) 4.67 (2.56,8.53) ,0.001
D. pteronyssinus (N = 943) 53 (5.6) 8 (6.8) 45 (5.5) 1.27 (0.58,2.77) 0.542
Cockroach (N = 943) 26 (2.8) 2 (1.7) 24 (2.9) 0.58 (0.14,2.49) 0.465
Any sensitization{ (N = 943) 74 (7.8) 10 (8.6) 64 (7.7) 1.12 (0.56,2.24) 0.758
*one or more of asthma, eczema and hay fever.
¥Sensitization to either D. pteronyssinus or cockroach allergen.
doi:10.1371/journal.pone.0022551.t002
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However, we found that none of our markers of socioeconomic
status were associated with women’s use of paracetamol, which
make this unlikely to explain our findings.
Whilst our sensitization outcomes were measured objectively
and based on domestic allergens previously found to be common
in Ethiopia,[25] our measures of asthma, hay fever and eczema
were based on self report and hence susceptible to reporting or
information bias. Of particular concern was misclassification of
scabies or other skin condition as eczema. However, we have
previously shown that the short-term repeatability of wheeze and
asthma questionnaire in a similar setting is generally good, even
though validity of these symptoms in relation to exercise test or
bronchodilator challenge is limited[23]. The outcome measures
used focused on asthma rather than wheeze, primarily because our
previous validation work in the same setting and in a similar age
group showed short-term Kappa was higher for asthma than
wheeze responses[23]. The low prevalence of our allergic
symptoms and sensitization outcomes, however, has limited the
power of the study which was partly reflected by the wide
confidence interval around the risk estimates.
Paracetamol use was also ascertained by self report, but recall
error was minimized by the fact we based our exposure variable on
dose of paracetamol in the last month, and also medication strips
or other containers were cross-checked where possible. Further-
more, we have previously established that adults in Butajira are
able to differentiate paracetamol from other analgesics[20]. Since
there is no reason that allergic subjects would be more or less likely
to report paracetamol use, any reporting error is likely to be non-
differential and would therefore result in our odds ratios being
biased towards the null value.
Table 3. OR for asthma, eczema, hay fever and sensitization in relation paracetamol use in the past month in women.
Outcome
Paracetamol use
in past month
Yes
n (%)
Crude
OR (95%CI)
Adjusted
OR{ (95% CI) P-value
Asthma
(N= 945)
None 9 (1.3) 1 1 0.625{
1–3 tablets 2 (2.4) 1.84 (0.39,8.69) 1.76 (0.36,8.62) 0.364"
$4 tablets 5(2.6) 1.99 (0.66,6.02) 1.64 (0.52,5.14)
Eczema
(N= 945)
None 3 (0.5) 1 1 0.055{
1–3 tablets 3 (3.7) 8.48 (1.68,42.74) 8.51 (1.68,43.19) 0.225"
$4 tablets 2 (1.1) 2.38 (0.39,14.32) 2.19 (0.36,13.38)
Hay fever
(N = 945)
None 23 (3.4) 1 1 0.526{
1–3 tablets 5 (6.1) 1.84 (0.68,4.97) 1.86 (0.67,5.12) 0.775"
$4 tablets 8 (4.2) 1.24 (0.55,2.82) 1.03 (0.44,2.41)
Any allergic conditions*
(N = 945)
None 30 (4.5) 1 1 0.071{
1–3 tablets 9 (11.0) 2.64 (1.21,5.78) 2.73 (1.22,6.11) 0.225"
$4 tablets 13 (6.8) 1.57 (0.80,3.08) 1.35 (0.67,2.70)
D. pteronyssinus sensitization
(N = 943)
None 37 (5.5) 1 1 0.481{
1–3 tablets 7 (8.5) 1.60 (0.69,3.72) 1.60 (0.69,3.72) 0.856"
$4 tablets 9 (4.8) 0.86 (0.41,1.81) 0.85 (0.40,1.79)
Cockroach sensitization
(N = 943)
None 18 (2.7) 1 1 0.903{
1–3 tablets 2 (2.4) 0.91 (0.21,3.99) 0.91 (0.21,4.02) 0.708"
$4 tablets 6 (3.2) 1.19 (0.47,3.04) 1.22 (0.48,3.13)
Any sensitization¥ (N = 943) None 50 (7.4) 1 1 0.564{
1–3 tablets 9 (11.0) 1.54 (0.73,3.25) 1.53 (0.72,3.24) 0.668"
$4 tablets 15 (7.9) 1.07 (0.59,1.95) 1.07 (0.59,1.96)
{OR adjusted for age of the women, area of residence and women education.
*include asthma, eczema and hay fever.
¥Sensitization to either D. pteronyssinus or cockroach allergen.
{Likelihood ratio test.
"P value for trend.
doi:10.1371/journal.pone.0022551.t003
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Eczema and ‘any allergic condition’ were associated with
paracetamol use. The risk of asthma, although not significantly
associated with paracetamol exposure, was also elevated among
paracetamol users. Our finding is congruent with several earlier
epidemiological studies indicating an association between para-
cetamol use and allergy in women[10] and adults[1;4;11–14]. In
2005, we reported similar significant and consistent dose-
dependent associations between paracetamol use and eczema,
rhinitis, shortness of breath and sensitization to cockroach
allergens for which alternative explanations were unlikely[4].
However, this earlier study, like the current one, was unable to
show a significant relation between paracetamol use and self-
reported asthma which may reflect under-diagnosis of asthma in
this rural setting[4]. The lack of dose-response relationship in this
study may reflect the relatively small numbers of women in each
subgroup or errors in reporting doses, leading to misclassification
of dose category. The increased risk of eczema in this cohort of
women suggests that risk is not restricted to the airways and is
consistent with the findings of the ISAAC multicountry study[6].
This would fit with mechanisms that suggest that paracetamol
predisposes to glutathione depletion which may influence the
promotion of atopy through increased production of Th2 cytokine
responses[17]. A non-significant positive association was also been
seen between women’s paracetamol use and any skin sensitization.
This is consistent with the European Community Respiratory
Health Survey which reported a non significant tendency to higher
prevalence of atopy (defined as specific IgE titre of .0.35 KU.
L21 to four allergen tested) among adults in centres with higher
paracetamol sales[13]. The authors suggested antioxidant deple-
tion by paracetamol might influence allergic diseases at least in
adults[13].
Among the observational studies in adults are two United
States-based studies[10;11]. These studies showed an adverse role
of paracetamol use on asthma, chronic obstructive lung disease
(COPD), and decreased lung function[10;11]. The study by Barr
et al[10] prospectively examined paracetamol use on new onset
asthma in women and found an increased rate of new physician
diagnosis of adult onset-asthma. The finding supports the
hypothesis that population-level increases in asthma in the United
States might be attributable partly to a shift from aspirin to
paracetamol[15]. Further evidence comes from a United King-
dom-based case-control study[12] and the European Network
case-control study,[14] both of which reported increased risk of
asthma and other allergic disease morbidity with frequent use of
paracetamol. Further support for this hypothesis came from a
population-level ecological study in English-speaking coun-
tries[13]. Newson and colleagues in this study[13] took paracet-
amol sale as a proxy for frequent use, and demonstrated that sales
at country level were associated with increased risk of asthma,
eczema, rhinoconjunctivitis, and bronchial responsiveness.
In conclusion, this study shows a borderline significant
association between paracetamol use and symptoms of eczema
and ‘any allergic conditions’ in low-resource setting cohort of
women in which we have previously reported that aspirin
avoidance or bias in reporting exposure are unlikely to play a
role. We have also reported similar adverse effects in an equivalent
cohort of children in this population[5]. Together these findings
add additional support to the paracetamol-allergy hypothesis and
highlight the need for a randomized controlled trial.
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